Recent Press ReleasesApply07.01.2020Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-206.30.2020FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma06.30.2020European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 06.25.2020Pfizer Declares Third-Quarter 2020 Dividend06.24.2020Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa06.22.2020European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma06.22.2020Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines06.22.2020European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma06.18.2020Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy06.18.2020Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and UpjohnMedia ContactsGet to Know UsCompany Fact SheetFeatured StoriesPodcastsPress Kits @Pfizer @Pfizer_Newsby pfizerTweets by pfizer_news
